Tranexamic%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520acid

# Tranexamic acid ## Overview Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. It is used to control or prevent bleeding in various clinical situations. ## Primary Indications * **Hemorrhagic conditions:** Prevention and treatment of bleeding associated with hyperfibrinolysis, such as menorrhagia, epistaxis, gastrointestinal bleeding, and hemophilia. * **Surgical bleeding:** Reduction of blood loss during and after surgery, particularly in specialties like orthopedic, cardiac, and prostate surgeries. * **Trauma:** Reduction of mortality in patients with severe traumatic bleeding. ## Adult Dosing Dosing varies significantly based on indication and route of administration. * **Menorrhagia:** * Oral: 1 gram (g) three times daily, up to a maximum of 4 g daily, for up to 4 days during menstruation. * **Gingival bleeding:** * Oral: 1 g three times daily. * **Epistaxis:** * Oral: 1 g three times daily. * Topical: Solution can be used as a nasal spray or gargle. * **Hemorrhagic conditions (general/surgical):** * Intravenous (IV): 1 g to 1.5 g every 6 to 8 hours. Higher doses may be used in specific surgical settings. * **Major trauma:** * IV: Loading dose of 1 g over 10 minutes, followed by an infusion of 1 g per hour for up to 8 hours, or until bleeding is controlled. (CRASH-2 trial dosing). *Note: Specific protocols, especially for surgical use and major trauma, may dictate exact dosing and timing.* ## Pediatric Dosing Dosing in pediatric patients is less established and often based on adult data or weight-based calculations. Consultation with pediatric specialists is recommended. * **General guideline (oral):** 20-25 mg/kg/dose every 8 hours, not to exceed adult doses. * **General guideline (IV):** 10 mg/kg/dose every 6-8 hours. ## Dose Adjustments * **Renal Impairment:** Dose adjustment is crucial. * Creatinine clearance (CrCl) 50-80 mL/min: 75% of standard dose. * CrCl 20-50 mL/min: 50% of standard dose. * CrCl 10-20 mL/min: 25% of standard dose. * CrCl <10 mL/min: Consider avoiding or use with extreme caution, potentially 10% of standard dose and prolonged intervals. * **Hepatic Impairment:** No dose adjustment is typically required. ## Contraindications * Active intravascular thrombosis or thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis). * History of thrombosis. * Hypersensitivity to tranexamic acid. * Acquired defective color vision (for long-term oral use). * Subarachnoid hemorrhage (controversial; risk of vasospasm and cerebral ischemia may outweigh benefits). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** * Thromboembolic events (stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism). * Hypersensitivity reactions (anaphylaxis). * Visual disturbances (especially with long-term oral use). * Seizures (particularly with rapid IV administration or high doses). * Hypotension (with rapid IV infusion). ## Key Drug Interactions * **Hormonal contraceptives (oral, transdermal, vaginal):** Increased risk of thromboembolic events. * **Factor VIIa (recombinant):** Increased risk of thrombosis. * **Antifibrinolytics (e.g., aminocaproic acid):** Concurrent use is generally not recommended due to increased thrombotic risk. * **Estrogens:** May potentiate hypercoagulability. * **Oral contraceptives:** May potentiate hypercoagulability. ## Monitoring * **Clinical:** Assess for bleeding and signs of therapeutic response. Monitor for adverse effects, particularly thromboembolic events, visual changes, and GI upset. * **Laboratory:** Baseline and periodic renal function tests (creatinine) are essential for dose adjustment. ## Clinical Pearls * Tranexamic acid is most effective when administered early in the bleeding event. * Rapid IV injection can cause hypotension and increase the risk of seizures. Administer IV doses slowly. * For oral use, consider dividing the daily dose to improve GI tolerance. * The risk of thromboembolic events is a significant concern. Carefully weigh the benefits against the risks, especially in patients with pre-existing risk factors for thrombosis. * Consult prescribing information for detailed guidance on specific indications, especially in complex surgical or trauma scenarios. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.